Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07737756) titled 'A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients Treated With Onasemnogene Abeparvovec in Saudi Arabia' on July 27.

Study Type: Observational

Primary Sponsor: Novartis Pharmaceuticals

Condition: Spinal Muscular Atrophy

Recruitment Status: Not recruiting

Date of First Enrollment: August 20, 2026

Target Sample Size: 6

To know more, visit https://clinicaltrials.gov/study/NCT07737756

Disclaimer: Curated by HT Syndication....